Literature DB >> 499301

Pharmacokinetics of methadone during maintenance therapy: pulse labeling with deuterated methadone in the steady state.

E Anggård, M I Nilsson, J Holmstrand, L M Gunne.   

Abstract

A technique is presented for study of steady state kinetics of methadone using pulse labeling with deuterated methadone (d3) and mass fragmentography to measure both unlabeled and labeled methadone in blood. Seven subjects maintained on methadone for at least 10 months were admitted to a closed metabolic ward. The daily dose of unlabeled methadone (d0) was substituted by one dose of methoadone-d3 and plasma levels of methadone-d0 and methadone-d3 were followed for 48 h using a precise (SD +/- 5%) and sensitive (30 pmol/ml) mass fragmentographic technique. Plasma half-lives (T1/2) for both methadone-do and methadone-d3 were calculated from samples obtained 8--24 H following the dose of methadone-d3. The t1/2 of oral methadone-d3 was shorter (22 +/- 2 h) than that of methadone-d0 (52 +/- 20 h). The same pattern was observed after intravenous administration. The results indicate multiple pools of methadone in the body.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 499301     DOI: 10.1007/bf00644967

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment.

Authors:  K Verebely; J Volavka; S Mulé; R Resnick
Journal:  Clin Pharmacol Ther       Date:  1975-08       Impact factor: 6.875

2.  Plasma levels and symptom complaints in patients maintained on daily dosage of methadone hydrochloride.

Authors:  W H Horns; M Rado; A Goldstein
Journal:  Clin Pharmacol Ther       Date:  1975-06       Impact factor: 6.875

3.  Determination of homovanillic acid turnover in man.

Authors:  E Anggård; T Lewander; B Sjöquist
Journal:  Life Sci       Date:  1974-07-01       Impact factor: 5.037

4.  Effect of oral administration of methadone on hepatic microsomal mixed function oxidase activity in mice.

Authors:  L W Masten; G R Peterson; A Burkhalter; E L Way
Journal:  Life Sci       Date:  1974-05-01       Impact factor: 5.037

5.  Physiological disposition and metabolism of levo-methadone-1- 3 H in nontolerant and tolerant rats.

Authors:  A L Misra; S J Mulé; R Bloch; N L Vadlamani
Journal:  J Pharmacol Exp Ther       Date:  1973-05       Impact factor: 4.030

6.  The levels of methadone in the plasma in methadone maintenance.

Authors:  C E Inturrisi; K Verebely
Journal:  Clin Pharmacol Ther       Date:  1972 Sep-Oct       Impact factor: 6.875

7.  Disposition of methadone in man after a single oral dose.

Authors:  C E Inturrisi; K Verebely
Journal:  Clin Pharmacol Ther       Date:  1972 Nov-Dec       Impact factor: 6.875

8.  Disposition of methadone in methadone maintenance.

Authors:  E Anggård; L M Gunne; J Homstrand; R E McMahon; C G Sandberg; H R Sullivan
Journal:  Clin Pharmacol Ther       Date:  1975-03       Impact factor: 6.875

9.  Methadone plasma level: sustained by a reservoir of drug in tissue.

Authors:  V P Dole; M J Kreek
Journal:  Proc Natl Acad Sci U S A       Date:  1973-01       Impact factor: 11.205

10.  Clinical effects and pharmacokinetics of racemic methadone and its optical isomers.

Authors:  G D Olsen; H A Wendel; J D Livermore; R M Leger; R K Lynn; N Gerber
Journal:  Clin Pharmacol Ther       Date:  1977-02       Impact factor: 6.875

View more
  8 in total

Review 1.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

2.  Steady-state pharmacokinetics of methadone in opioid addicts.

Authors:  K Wolff; A W Hay; D Raistrick; R Calvert
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

3.  Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts.

Authors:  J W de Vos; P J Geerlings; W van den Brink; J G Ufkes; H van Wilgenburg
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

4.  Patient-controlled dose regimen of methadone for chronic cancer pain.

Authors:  J Säwe; J Hansen; C Ginman; P Hartvig; P A Jakobsson; M I Nilsson; A Rane; E Anggård
Journal:  Br Med J (Clin Res Ed)       Date:  1981-03-07

5.  Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method.

Authors:  U Meresaar; M I Nilsson; J Holmstrand; E Anggård
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

6.  Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase.

Authors:  M I Nilsson; E Anggård; J Holmstrand; L M Gunne
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Mechanism of autoinduction of methadone N-demethylation in human hepatocytes.

Authors:  Scott D Campbell; Amanda Crafford; Brian L Williamson; Evan D Kharasch
Journal:  Anesth Analg       Date:  2013-06-03       Impact factor: 5.108

8.  Role of cytochrome P4502B6 in methadone metabolism and clearance.

Authors:  Evan D Kharasch; Kristi Stubbert
Journal:  J Clin Pharmacol       Date:  2013-01-07       Impact factor: 3.126

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.